Table 1.
Statistical significance for framework mutations for FDA-approved mAbs.
| Germline Gene | FDA-approved Antibodies | Number of VH Framework Mutations | p-value | Number of Repertoire Sequences Analyzed |
|---|---|---|---|---|
| VH1-2 | Pembrolizumab | 16 | 7.0E-06 | 300,000 |
| VH1-3 | Vedolizumab | 9 | 4.7E-02 | 129,913 |
| VH1-46 | Benralizumab Ravulizumab Burosumab |
24 | 1.1E-06 | 451,920 |
| VH1-69 | Risankizumab Ixekizumab Galcanezumab |
23 | 1.8E-05 | 300,000 |
| VH2-5 | Palivizumab | 7 | 5.1E-03 | 141,372 |
| VH3-7 | Secukinumab Fremanezumab Durvalumab |
10 | 7.4E-05 | 2,003,693 |
| VH3-9 | Adalimumab Ofatumumab Sarilumab |
9 | 7.6E-07 | 403,612 |
| VH3-23 | Pertuzumab Denosumab Daratumumab Avelumab Dupilumab Emicizumab Lanadelumab Atezolizumab |
38 | 9.3E-07 | 300,000 |
| VH3-30 | Ipilimumab Erenumab |
5 | 1.3E-04 | 300,000 |
| VH3-33 | Canakinumab Nivolumab |
4 | 2.1E-02 | 710,048 |
| VH3-48 | Certolizumab pegol | 11 | 2.1E-03 | 300,000 |
| VH3-66 | Omalizumab Trastuzumab Eptinezumab |
27 | 7.6E-08 | 321,361 |
| VH3-74 | Efalizumab Elotuzumab Atezolizumab |
26 | 7.7E-05 | 1,355,540 |
| VH4-4 | Alemtuzumab | 7 | 2.2E-04 | 1,003,945 |
| VH4-30-4 | Tocilizumab Necitumumab |
11 | 2.6E-06 | 160,757 |
| VH5-51 | Ustekinumab Guselkumab |
7 | 2.6E-05 | 702,327 |